Expert kidney mass workup — Atlanta, GA

Evaluation of Renal Masses

Comprehensive kidney mass evaluation using advanced imaging, genomic testing, and multidisciplinary expertise to create personalized treatment plans.

Schedule consultationCall 678-344-8900
✓
Comprehensive imaging with CT, MRI, and ultrasound
✓
Percutaneous biopsy for pathologic diagnosis when needed
✓
Risk stratification to guide surgery, ablation, or surveillance

What Are Renal Masses?

A renal mass is any abnormal growth in the kidney discovered on imaging. Most are found incidentally during scans for unrelated symptoms. Renal masses can be:

  • Benign: Simple cysts, angiomyolipomas, oncocytomas (20-30% of solid masses)
  • Malignant: Renal cell carcinoma (RCC) — the most common kidney cancer in adults
  • Indeterminate: Require further workup to clarify nature and appropriate management

Initial Imaging Workup

CT Scan with Contrast

Gold standard for characterizing renal masses. Shows:

  • Size, location, and growth pattern
  • Enhancement (suggests solid tumor vs. cyst)
  • Involvement of blood vessels, lymph nodes, or adjacent organs
  • Chest imaging included to screen for metastases

MRI

Used when:

  • Patient has contrast allergy or kidney disease
  • Equivocal findings on CT requiring further characterization
  • Superior for characterizing cystic lesions (Bosniak classification)
  • Assessing tumor thrombus in renal vein or IVC

Bosniak Classification (for Cystic Masses)

  • Bosniak I: Simple cyst; no follow-up needed
  • Bosniak II: Minimally complex; annual imaging surveillance
  • Bosniak IIF: Moderately complex; close follow-up every 6 months
  • Bosniak III: Indeterminate; 50% cancer risk — biopsy or surgery recommended
  • Bosniak IV: Clearly malignant; surgical excision indicated

Renal Mass Biopsy

When We Recommend Biopsy

  • Small masses (<4 cm) being considered for active surveillance or ablation
  • Metastatic disease where tissue diagnosis is needed before systemic therapy
  • Atypical imaging features (suspected lymphoma, abscess, metastasis to kidney)
  • Clinical trial enrollment requiring pathologic confirmation

The Procedure

  • Outpatient, conscious sedation
  • CT or ultrasound-guided needle biopsy
  • 15-20 minutes; minimal discomfort
  • Results in 3-5 days; includes histology and molecular profiling
  • Diagnostic accuracy >90% with modern techniques

Risk Stratification & Treatment Planning

We integrate imaging, biopsy, patient age, comorbidities, and preferences to recommend:

  • Active Surveillance: For small (<2 cm), slow-growing masses in elderly or high-risk surgical patients
  • Ablation: For T1a tumors (<4 cm) in select patients wanting kidney-sparing minimally invasive options
  • Robotic Partial Nephrectomy: Gold standard for T1 tumors; preserves kidney function
  • Radical Nephrectomy: For large, complex, or locally advanced cancers
  • Systemic Therapy: For metastatic disease (immunotherapy, targeted therapy, clinical trials)

Follow-Up Surveillance

After treatment (or if on active surveillance), we monitor with:

  • CT or MRI at regular intervals (every 3-6 months initially, then annually)
  • Chest imaging to detect lung metastases (most common site of spread)
  • Lab work (creatinine to assess kidney function, CBC)
  • Longer follow-up for high-grade tumors (5-10 years minimum)
  • Patients on active surveillance undergo imaging every 3-6 months to detect growth requiring intervention

Why Advanced Urology?

  • Fellowship-trained kidney cancer specialists with expertise in imaging interpretation and risk stratification
  • In-house biopsy capabilities with rapid pathology turnaround and molecular profiling
  • Multidisciplinary tumor boards reviewing every complex case to ensure optimal treatment selection
  • Access to advanced therapies — robotic surgery, thermal and non-thermal ablation, immunotherapy, targeted therapy, clinical trials
  • Personalized surveillance protocols tailored to your individual risk profile and preferences

Frequently Asked Questions

Are all kidney masses cancer?

No. About 20-30% of solid masses are benign. Simple cysts are extremely common and almost never cancerous. Biopsy and advanced imaging help distinguish benign from malignant.

Should I get a second opinion?

Yes, especially for complex or large masses. We welcome second opinions and routinely review outside imaging and pathology to ensure accurate diagnosis and optimal treatment planning.

How quickly do kidney tumors grow?

Most renal cell carcinomas grow slowly (2-5 mm per year on average). This allows time for thorough evaluation and informed decision-making. Aggressive tumors grow faster and require prompt intervention.

Can I wait and watch a small mass?

Yes, for select patients. Active surveillance is safe for small (<2 cm), slow-growing masses in elderly patients or those with significant comorbidities. Close imaging follow-up ensures intervention if growth occurs.

Next Steps

If you have been diagnosed with a kidney mass or have concerning findings on imaging, our kidney cancer specialists will provide comprehensive evaluation, explain all treatment options, and create a personalized plan focused on cancer control and preserving kidney function.

Schedule evaluationEmail our team